Rapid and Efficient BAC Recombineering: Gain & Loss Screening System

Running title: Rapid and Efficient BAC Recombineering

Myeong Uk Kuk¹, Sekyung Oh^{2,3,*}, Joon Tae Park^{1,*}

¹Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon, Korea ²Department of Medicine, Catholic Kwandong University College of Medicine, Incheon, Korea ³Institute for Biomedical Research, Catholic Kwandong University International St. Mary's Hospital, Incheon, Korea,

*Correspondence to: Sekyung Oh, Ph.D. Department of Medicine Catholic Kwandong University College of Medicine Incheon, Korea Tel: +82-10-6562-7585 E-mail: ohskjhmi@ish.ac.kr

Joon Tae Park, Ph.D. Division of Life Sciences College of Life Sciences and Bioengineering Incheon National University Incheon, Korea Tel: +82-32-835-8841 E-mail: joontae.park@inu.ac.kr

Abstract

Recombineering has been developed to modify bacterial artificial chromosome (BAC) via homologous recombination. Nevertheless, as a screening strategy to identify the correct clone was not properly developed, it was difficult to obtain a correct clone within a limited time period. To address these issues, we developed a new screening method (a gain & loss screening system) that enables the efficient identification of the recombineered clone. Simple inoculation of cells into LB medium with appropriate antibiotics visually revealed the positive clones within 24 h. DNA sequencing confirmed 100% accuracy of this screening method by showing that all positive clones exhibited recombinant sequences. Furthermore, our new method allowed us to complete the entire procedure consisting of 1st recombineering, flip-out and 2nd recombineering in just 13 days. Overall, our new strategy may provide a new avenue for BAC recombeering, as evidenced by markedly increased accuracy and subsequently shortened recombineering duration.

Keywords: recombineering • lamda-red recombinase • gain & loss screening system

INTRODUCTION

The production of biopharmaceutical proteins has been a key topic in biotechnology with mammalian cell culture being a widely used method for their production (Wurm 2004). Currently, over 100 therapeutic proteins are being produced in mammalian systems, and their number is expected to increase dramatically as new therapeutic antibodies are developed (Rita Costa et al. 2010). Thus, significant efforts have been made in the last decades to improve protein production in mammalian cell lines. Plasmid-based vectors are the most widely used tools for protein production. They include promoters that induce the expression of gene-of-interest (GOI). However, expression of GOI in plasmid-based vectors is greatly affected by surrounding chromatin at the integration site. Once the vector is integrated into a "silent chromatin" region, the expression tends to silence over time (i.e., positional chromatin effects) (Giraldo and Montoliu 2001). Accordingly, several strategies have been developed to avoid the local effects of chromatin. One of the most widely used methods is to use bacterial artificial chromosome (BAC) that can accommodate whole mammalian loci. BAC can accommodate a complete gene containing all *cis*-acting regulatory elements in their native configuration. Therefore, BAC is minimally affected by the surrounding chromatin at the integration site, so BAC can accurately deliver the expected expression pattern (Giraldo and Montoliu 2001).

Nevertheless, since the BAC size is very large, their modification cannot be made using standard cloning procedures (e.g., restriction enzyme digestion or ligation). BAC recombineering only allows the exchange of genetic information between two DNA molecules in an accurate, specific, and faithful way, regardless of the size of the DNA. However, BAC recombineering is very labor-intensive and time-consuming due to a large number of false positive background colonies during screening procedure. Therefore, BAC recombineering constituted a substantial barrier for less experienced researchers to consider BAC suitable as expression vectors for protein production.

Here we present a new screening method, the gain & loss screening system, which can provide markedly increased accuracy and shortened working time. This new strategy may provide powerful new tool for facilitating e.g. biopharmaceutical protein expression and other largevector applications, and rendering such approaches feasible for less experienced laboratories.

MATERIALS AND METHODS

Bacterial strain and BAC clones

SW105 bacteria: Genotype F-mcrA Δ (mrr-hsdRMS-mcrBC) Φ 80dlacZ M15 Δ lacX74 deoR recA1 endA1 araD139 Δ (ara, leu) 7649 galU galK rspL nupG [λ cl857 (cro-bioA) $\langle \rangle$ tet] [(cro-bioA) $\langle \rangle$ araC-PBADflpe]. SW105 bacteria was generously provided by the Copeland laboratory at the National Cancer Institute. BAC clone (RP24-85L15) was purchased from BACPAC resources center (CHORI, Oakland, CA, USA).

Preparation of BAC targeting cassette (BTC) and chloramphenicol (Cam) targeting cassette (CTC)

BAC targeting vector (BTV) (Addgene, cat. no. 131589) and Cam targeting cassette (CTV) (Addgene, cat. no. 131590) are available from Addgene. Incubate BTV with XhoI & XmaI and CTV with BamHI & XhoI for 4 h at 37°C. Load the digested DNA onto a 0.2% agarose gel. Run the gel for 30 min at 100 V on a DNA electrophoresis device (Bioand, cat. no. Mini-ES). Following electrophoresis, cut out the DNA band containing the BTC and CTC under a LED trans illuminator (Maestrogen, cat. no. SLB-01W). Purify the DNA using a gel extraction kit (Qiagen, cat. no. 28704). Measure the DNA concentration using Nanodrop spectrophotometer (Denovix, cat. no. DS-11) and dilute the DNA to 8–10 ng/µl using DW.

Overview of the procedure

The comprehensive details on the methodology is describe in the Supplementary Material. To provide comprehensive details on the methodology, we have organized the BAC recombineering process into five consecutive stages, which are illustrated in a general flow-chart (Supplementary Fig. 1). In the first stage (steps 1–8), the identification of the desired BAC and the preparation of SW105 bacteria containing the BAC was performed. In the second stage (steps 9–15), the 1st recombineering was conducted to introduce a BTC into the predetermined region of BAC. In the third stage (steps 16–18), flip-out was conducted to delete the selection marker, kanamycin resistance (*KanR*) gene. In the fourth stage (steps 19–23), the 2nd recombineering was conducted to introduce a CTC. In the final stage (steps 24–27), maxi-preparation of BAC DNA was conducted.

RESULTS

1st gain & loss screening system

Two different BAC recombineering systems are widely used including those based on bacterial phage-encoded recombinases; one uses episomal plasmids to supply RecET of the Rac phage (Zhang et al. 1998; Muyrers et al. 2000) and the other utilizes a temperature-sensitive lamda repressor to control the expression of lamda-red recombinase (Yu et al. 2000; Lee et al. 2001). Lamda-red recombinase appears to be at least 50- to 100-fold more efficient than the RecET system (Zhang et al. 1996). Thus, methodology based on the lamda-red recombinase was selected in this study.

SW105 bacteria strain has been genetically modified to have the lamda-red recombinase system. It has a PL operon encoding lamda-red recombinase (*exo*, *bet*, and *gam*) that plays a crucial role in the recombineering process. The PL operon is under strict control of the temperature-sensitive lamda repressor (cI857). At low temperatures in the range of 30–34°C, cI857 is active and binds to the operator site thereby preventing transcription of the recombinant genes. Thermal upshift to 42°C reversibly inhibits the activity of cI857, thereby activating transcription of the recombinant genes.

For the recombineering, a 5' homology region (HR) and 3' HR was introduced into the BAC targeting vector (BTV, Addgene ID: 131589) containing GOI and a kanamycin resistant gene (*KanR*) (Fig. 1A). To purify BAC targeting cassette (BTC), the BTV with HRs was cut with appropriate XhoI and XmaI (Fig. 1A). As BTC contains *KanR* with two flanking FRT sites, the recombination of BTC with a BAC clone after brief heat shock at 42°C will result in a positive clone, which has dual antibiotic resistant genes, *KanR* (from BTC) and chloramphenicol resistant gene (*CamR*; from the BAC).

Following the recombineering, a LB plate containing Cam and Kan was used to discriminate the candidate clone(s). The number of candidate colonies appeared after 48 h incubation at 32°C was summarized in Fig. 1B. As BTV in supercoiled form cannot be efficiently cleaved with restriction enzymes, non-cleaved BTVs may be included in the purified BTC. BTV contamination will result in a non-recombinant clone, which has triple antibiotic resistant genes, an ampicillin resistant gene (*AmpR*; from BTV), *KanR* (from BTV) and *CamR* (from the BAC). To identify the clones derives from the desired recombination, the 1st gain & loss screening system was applied (Fig. 1C). The candidate clones on the plate was inoculated in the 1st gain & loss screening system and incubated for 24 h (Fig. 1C). This system will exhibit the three possible cases (Fig. 1C).

1) Case#1: positive in LB with Cam, positive with Amp, positive with Kan (no recombination)

2) Case#2: negative in LB with Cam, positive with Amp, positive with Kan (no recombination)

3) Case#3: positive in LB with Cam, negative with Amp, positive with Kan (recombination)

Case#3 only occurs if the recombineering is successful. The average efficiency of obtaining a case#3 was 31.94% (Fig. 1D). To confirm the correct recombination, colony PCR was conducted on all clones from case#3. The forward (Fwd) primer was located in the BAC vector and reverse (Rev) primer in BTC (Fig. 1E). The size of PCR product in 5' recombineered and 3' recombineered region was approximately 280 bp and 500 bp, respectively, indicating the successful recombineering (Fig. 1F). Following PCR, DNA sequencing was performed to verify the recombinant region. All positive clones were found to exhibit recombinant sequences indicating 100% accuracy of 1st gain & loss screening system (Fig. 1F). Taken together, these results imply that simple inoculation of cells into the screening system visually displayed the positive clones with 100% accuracy.

2nd gain & loss screening system

During the 1st recombineering step, successful recombination was carried out through the introduction of *KanR*. However, *KanR* should be deleted for subsequent experiments. The SW105 strain harbors an endogenous L-arabinose-inducible *FLP* gene. Since *KanR* is flanked by two FRT sites, the induced FLP gene in the presence of L-arabinose will delete *KanR* (Fig. 2A).

Following FLP induction, a LB plate containing Cam was used to discriminate the candidate clone(s). The number of candidate colonies appeared after 48 h incubation at 32°C was summarized in Fig. 2B. The 2nd gain & loss screening system was used to determine whether the flip-out reaction was successful (Fig. 2C). The positive clones on the plate was inoculated and incubated for 24 h (Fig. 2C). This system will exhibit the two possible cases (Fig. 2C).

1) Case#1: positive in LB with Cam, positive with Kan (no flip-out)

2) Case#2: positive in LB with Cam, negative with Kan (flip-out)

Case#2 only occurs if the flip-out is successful. The average efficiency of obtaining a case#2 was 100% (Fig. 2D). To confirm the correct flip-out, colony PCR was conducted on all the clone from case#2. Two primers were located outside of the two FRT sites (Fig. 2E). The size of PCR product in flip-out region was approximately 100 bp, indicating the successful flip-out (Fig. 2F). Following PCR, DNA sequencing was performed to verify the flip-out region. All positive clones were found to exhibit recombinant sequences indicating 100% accuracy of 2nd gain & loss screening system (Fig. 2F). Taken together, these results confirmed the accuracy of the 2nd gain & loss screening system to 100%.

3rd gain & loss screening system

To facilitate integration of the BAC construct into the genome, the Tol2 transposon system was used (Suster et al. 2011). The Tol2 transposon system yields the highest rate of genomic integration in the germ lineage resulting in the increased production of desired proteins (Suster et

al. 2011; Balasubramanian et al. 2016). As *CamR* is located on a backbone vector of BAC clones, *CamR* was targeted to introduce the Tol2 transposon system. For the recombineering, a 5' & 3' *CamR* HR was introduced into the Cam targeting vector (CTV, Addgene ID: 131590) containing inverted left & right Tol2 transposons, *AmpR* for gain & loss screening, and a neomycin resistance (*NeoR*) gene for a mammalian selection marker (Fig. 3A). To purify chloramphenicol targeting cassette (CTC), CTV was cut with BamHI and XhoI (Fig. 3A).

As the recombination of CTC with a flip-out positive clone will lose *CamR* but acquire *AmpR* (from CTC), a LB plate containing Amp was used to discriminate the candidate clone(s). The number of candidate colonies appeared after 48 h incubation at 32°C was summarized in Fig. 3B. As CTV in supercoiled form cannot be efficiently cleaved with restriction enzymes, noncleaved CTVs may be included in the purified CTC. CTV contamination will result in a nonrecombinant clone, which has double antibiotic resistant genes, *AmpR* (from CTV) and *CamR* (from the BAC). To differentiate whether the clone derives from the desired recombination, the 3^{rd} gain & loss selection system was used. The candidate clones on the plate was inoculated in the 3^{rd} gain & loss selection system and incubated for 24 h (Fig. 3C). This system will exhibit the three possible cases (Fig. 3C).

- 1) Case#1: positive in LB with Cam, negative with Amp (no recombination)
- 2) Case#2: positive in LB with Cam, positive with Amp (no recombination)
- 3) Case#3: negative in LB with Cam, positive with Amp (recombination)

Case#3 only occurs if the recombineering is successful. The average efficiency of obtaining a case#3 was 75.69% (Fig. 3D). To confirm the correct recombination, colony PCR was conducted on all the clone from case#3. The Fwd primer was located in the BAC vector and the Rev primer in the CTC (Fig. 3E). If a recombineering occurred, the PCR product of 5' recombineered and 3' recombineered region should be approximately 400 bp and 390 bp, respectively (Fig. 3F). Following PCR, DNA sequencing was performed to verify the recombinant region. All positive clones were found to exhibit recombinant sequences indicating 100% accuracy of 3rd gain & loss screening system (Fig. 3F). Taken together, these results also confirmed the accuracy of the third screening system to 100%.

More strategies to increase recombination efficiency

The efficiency of the 2nd BAC recombineering (75.69%) was 2 times higher than that of the 1st BAC recombineering (31.94%). This discrepancy is presumed to be due to the difference in HR length, the decisive for the recombination efficiency (Sharan et al. 2009; Kung et al. 2013). However, the length of 5' HR (473 bp) and 3' HR (486 bp) in BTV was longer than 5' HR (200 bp) and 3' HR (200 bp) in CTV, so other factors may be involved in this discrepancy. Incomplete enzymatic digestion of the targeting vector increases the number of false positive clones, thereby

reducing recombination efficiency (Jacobus and Gross 2015). Strategies to induce complete enzymatic digestion are required, but incomplete digestion may occur due to several other factors including DNA methylation (23). Thus, we hypothesized that strategy to distinguish between linear DNA and uncut circular DNA would increase the recombination efficiency. As a low percentage of agarose gel can distinguish fast-moving linear DNA fragments from slow-moving circular DNA (Lee et al. 2012), we used 0.2% agarose gel and differentiated the linearized BTC (4.7 kb; red rectangle) from uncut BTV (7.6 kb; yellow rectangle) (Fig. 4A). Then, the 1st BAC recombineering was performed again. The efficiency of the 1st BAC recombineering increased from 31.94% to 59.38%, indicating that a strategy to purify the targeting cassette on a low percentage of agarose gel can be another decisive factor for the efficient recombineering (Fig. 4A).

Targeting vector is high copy number plasmid, while BAC is low copy number plasmid. A high copy number plasmid replicates autonomously from the bacterial chromosome and is generally present in more than one copy per cell, providing higher antibiotic resistance (Jahn et al. 2016). CTV has *AmpR* for selection, so bacteria with uncut CTV with non-recombinant BACs can grow better than bacteria with recombinant BACs. Thus, we hypothesized that the selection of small colony will increase the recombination efficiency. Following the 2nd recombineering, the candidate clones were distinguished using LB plates containing Amp. After 48 h incubation at 32°C, colonies appeared as shown graphically in Fig. 4B. To test our hypothesis, large colonies (larger than 1 mm) were selected from one group and small colonies (smaller than 1 mm) from the other group. The recombination efficiency obtained when selecting small colonies was increased by about 1.6-fold compared to when selecting large colonies (47.92% vs. 29.17%, Fig. 4B).

DISSCUSSION

The rapid and efficient screening system is crucial for the BAC recombineering procedure. The importance of the screening system was realized by a strategy to reduce the number of false positive clones by performing long digestion of the targeting vector (Carreira-Rosario et al. 2013). However, due to many false positive clones, it still takes too much time to find a real recombinant clone (Carreira-Rosario et al. 2013). Another strategy have been attempted to avoid false positive clones from non-cleaved targeting vectors using PCR amplification of the targeting vector with PCR primers containing HR (Sharan et al. 2009). This strategy was also hampered by a false positive clones derived from PCR templates or unavoidable PCR errors during PCR amplification of the targeting vector (Sharan et al. 2009). In the current study, we uncovered a novel strategy in which simple inoculation of cells visually revealed the positive clones within 24 h. This strategy is based on whether cells can survive in the medium with specific antibiotics. Combination of survival or non-survival in a medium containing antibiotics was used a tool to determine whether a clone has a real recombined BAC or comes from a false positive background. The accuracy of this screening was confirmed by DNA sequencing results showing that all positive clones exhibited recombinant sequences. To our knowledge, our study provides the first demonstration that new gain & loss screening scheme enables 100% accuracy opening a new horizon in the field of BAC recombineering.

BAC recombination consists of time-consuming steps including 1st recombineering, flip out and 2nd recombineering. This time-consuming procedure has been a major obstacle for researchers starting BAC recombineering. Procedures to reduce BAC recombination duration are the most demanding criteria for researchers to conduct BAC recombination. The 100% accurate gain & loss screening system facilitated recombineering process by making each recombination process successful at once. Furthermore, the increased recombination efficiency by using long HR promoted recombination progress by allowing identification of the recombinant clones out of only 48 colonies per step. The efficiency of the 1st and 2nd BAC recombineering was 31.94% and 75.69%, respectively, whereas that of traditional BAC recombineering with short HRs was less than 10% (Liu et al. 2003). Thus, our new strategy allowed us to complete the entire BAC recombineering procedure within just 13 days (Fig. 5). Taken together, considering short duration, we expect that this protocol will open a new path for laboratories with less experience in the field of BAC recombineering.

Recombineering is a genetic and molecular biology technique based on homologous recombination systems, which mediate efficient recombination of linear DNA molecules flanked by long HR (Thomason et al. 2014). The significance of long HR is highlighted by the finding that the targeting cassette with long HR (200–500 bp) is more efficient for recombineering than the targeting cassette with short HR (approximately 50 bp) (Degryse 1996; Sharan et al. 2009;

Dickinson et al. 2015). Targeting vectors with long HR were linearized by restriction digestion and purified in preparation for subsequent use in BAC recombineering steps. Long-term DNA digestion is crucial for complete digestion, but incomplete digestion can occur if enzyme activity is blocked by DNA methylation (Snounou and Malcolm 1984). As non-cleaved targeting vectors are inevitable, a new strategy is needed to avoid false positive clones. Here, we found that a novel tool using a low percentage of agarose gel increased the likelihood of obtaining recombinant clones by effectively avoiding uncut targeting vectors. The significance of a novel approach was supported by the results showing that the 1st BAC recombination efficiency increased from 31.94% to 59.38%. Taken together, our results imply that this new approach can be considered an alternative to solving problems that may arise when using long HR in targeting vectors.

BAC is based on an F-factor plasmid that maintains a small number of copies in bacterial cells, while the targeting vector is a high copy number plasmid (Asami et al. 2011). A low copy number plasmid has only one or a few copies in each bacterium, so antibiotic resistance is low compared to high copy number plasmids (Jahn et al. 2016). Thus, bacteria with low copy number plasmid grow slower than bacteria with high copy number plasmid in the presence of antibiotics (Trivedi et al. 2014). In this study, we proposed a novel strategy that use the growth differences between bacteria with recombinant BAC and bacteria without recombinant BAC. Bacteria with recombinant BAC are presumed to grow slower than bacteria with both unrecombined BAC and targeting vectors. This strategy was validated by the results showing that the recombination efficiency obtained when selecting small colonies was 1.6 times higher than when selecting large colonies. Based on these findings, we conclude that a strategy using growth differences in the presence of antibiotics will be another alternative that promotes fast and efficient BAC recombination.

In summary, we have developed a new strategy that makes it easy to visually confirm the success of BAC recombineering and reduce the overall processing time to less than two weeks (13 days) (Fig. 5). This new screening system will provide significant advances in current methodologies for BAC recombineering and might be of broad interest to many researchers in different fields including biopharmaceutical protein expression and other large-vector applications for various transgenic animals.

Author Contributions

MUK and JTP conceived of and designed the experiments. MUK performed the experiments. MUK, SO, and JTP wrote and edited the paper.

Acknowledgements

This research was supported by a Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (NRF-2018R1D1A1B07040293). This research was also supported by Research Assistance Program (2019) in the Incheon National University.

Financial disclosure

The authors declare no conflicts of interest.

Information pertaining to writing assistance

The authors declare no writing assistance

Ethical disclosure

The authors state that they have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Data sharing statement

The authors declare that they shall make data available to the scientific community without any restrictions.

References

- Asami J, Inoue YU, Terakawa YW, Egusa SF, Inoue T. 2011. Bacterial artificial chromos omes as analytical basis for gene transcriptional machineries. *Transgenic Res* **20**: 9 13-924.
- Balasubramanian S, Rajendra Y, Baldi L, Hacker DL, Wurm FM. 2016. Comparison of th ree transposons for the generation of highly productive recombinant CHO cell poo ls and cell lines. *Biotechnol Bioeng* 113: 1234-1243.
- Carreira-Rosario A, Scoggin S, Shalaby NA, Williams ND, Hiesinger PR, Buszczak M. 2 013. Recombineering homologous recombination constructs in Drosophila. J Vis Ex p doi:10.3791/50346: e50346-e50346.
- Degryse E. 1996. In vivo intermolecular recombination in Escherichia coli: application to plasmid constructions. *Gene* **170**: 45-50.
- Dickinson DJ, Pani AM, Heppert JK, Higgins CD, Goldstein B. 2015. Streamlined Geno me Engineering with a Self-Excising Drug Selection Cassette. *Genetics* **200**: 1035-1049.
- Giraldo P, Montoliu L. 2001. Size Matters: Use of YACs, BACs and PACs in Transgenic Animals. *Transgenic Res* 10: 83-103.
- Jacobus AP, Gross J. 2015. Optimal cloning of PCR fragments by homologous recombinat ion in Escherichia coli. *PLoS One* **10**: e0119221-e0119221.
- Jahn M, Vorpahl C, Hübschmann T, Harms H, Müller S. 2016. Copy number variability of expression plasmids determined by cell sorting and Droplet Digital PCR. *Micro bial Cell Factories* 15: 211.
- Kung SH, Retchless AC, Kwan JY, Almeida RPP. 2013. Effects of DNA size on transfor mation and recombination efficiencies in Xylella fastidiosa. *Appl Environ Microbiol* 79: 1712-1717.
- Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, Jenkins NA, Copeland NG. 2001. A highly efficient Escherichia coli-based chromosome enginee ring system adapted for recombinogenic targeting and subcloning of BAC DNA. *Genomics* **73**: 56-65.
- Lee PY, Costumbrado J, Hsu C-Y, Kim YH. 2012. Agarose gel electrophoresis for the se paration of DNA fragments. *J Vis Exp* doi:10.3791/3923: 3923.
- Liu P, Jenkins NA, Copeland NG. 2003. A highly efficient recombineering-based method f or generating conditional knockout mutations. *Genome Res* 13: 476-484.
- Muyrers JP, Zhang Y, Benes V, Testa G, Ansorge W, Stewart AF. 2000. Point mutation o f bacterial artificial chromosomes by ET recombination. *EMBO Rep* 1: 239-243.
- Rita Costa A, Elisa Rodrigues M, Henriques M, Azeredo J, Oliveira R. 2010. Guidelines

to cell engineering for monoclonal antibody production. *Eur J Pharm Biopharm* **7 4**: 127-138.

- Sharan SK, Thomason LC, Kuznetsov SG, Court DL. 2009. Recombineering: a homologou s recombination-based method of genetic engineering. *Nat Protoc* **4**: 206-223.
- Snounou G, Malcolm AD. 1984. Supercoiling and the mechanism of restriction endonuclea ses. *Eur J Biochem* **138**: 275-280.
- Suster ML, Abe G, Schouw A, Kawakami K. 2011. Transposon-mediated BAC transgenesi s in zebrafish. *Nat Protocols* **6**: 1998-2021.
- Thomason LC, Sawitzke JA, Li X, Costantino N, Court DL. 2014. Recombineering: genet ic engineering in bacteria using homologous recombination. *Current protocols in m olecular biology* **106**: 1.16.11-39.
- Trivedi RN, Akhtar P, Meade J, Bartlow P, Ataai MM, Khan SA, Domach MM. 2014. H igh-Level Production of Plasmid DNA by Escherichia coli DH5α ΩsacB by Introd ucing inc Mutations. *Appl Environ Microbiol* **80**: 7154-7160.
- Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. *Nat Biotechnol* 22: 1393-1398.
- Yu D, Ellis HM, Lee EC, Jenkins NA, Copeland NG, Court DL. 2000. An efficient reco mbination system for chromosome engineering in Escherichia coli. *Proc Natl Acad Sci U S A* 97: 5978-5983.
- Zhang Y, Buchholz F, Muyrers JP, Stewart AF. 1998. A new logic for DNA engineering using recombination in Escherichia coli. *Nat Genet* **20**: 123-128.
- Zhang Y, Riesterer C, Ayrall A-M, Sablitzky F, Littlewood TD, Reth M. 1996. Inducible Site-Directed Recombination in Mouse Embryonic Stem Cells. *Nucleic Acids Resea rch* 24: 543-548.

FIGURE LEGENDS

Fig. 1. Detailed procedure and results for the 1st recombineering. (A) Overview of the BAC targeting vector (BTV, Addgene ID: 131589) and BAC targeting cassette (BTC). (B) Summary of colony numbers in LB plates containing Cam and different concentrations of Kan following the 1st BAC recombineering. (C) Illustration of the 1st gain & loss selection system for identifying recombinant clones. Red asterisk (*) indicates the recombineering-positive clone. (D) Efficiency of the 1st recombineering after performing the 1st gain & loss selection system. Means \pm S.D., N = 3. (E) 1st recombineering scheme and position of colony PCR primers for recombination confirmation. (F) Picture of agarose gel electrophoresis showing colony PCR results. PCR product was only amplified in the recombineering-positive clone. Chromatogram results showing that the sequence of the amplified PCR product was conserved compared to the reference sequence at the genome-BTC boundary.

Fig. 2. Detailed procedure and results for the flip-out reaction.

(A) Overview of the flip-out reaction. In the presence of L-arabinose, the endogenous Larabinose-inducible *FLP* gene in the SW105 strain will delete *KanR* flanked by two FRT sites. (B) Summary of colony numbers in LB plates containing Cam after the flip-out reaction. (C) Inoculation of positive clones into the 2^{nd} gain & loss selection system. (C) Illustration of the 2^{nd} gain & loss selection system for identifying recombinant clones. Red asterisk (*) indicates a flipout positive clone. (D) Efficiency of flip-out reaction after performing the 2^{nd} gain & loss selection system. Means \pm S.D., N = 3. (E) Flip-out scheme and location of colony PCR primers for confirming flip-out reaction. (F) Picture of agarose gel electrophoresis showing colony PCR results. PCR product was only amplified in the flip-out positive clone. Chromatogram results showing that the sequence of the amplified PCR product was conserved compared to the reference sequence at the border where flip-out was completed.

Fig. 3. Detailed procedure and results for the 2^{nd} recombineering. (A) Overview of Cam targeting vector (CTV, Addgene ID: 131590) and Cam targeting cassette (CTC). (B) Summary of colony numbers in LB plates containing different concentrations of Amp after the 2^{nd} BAC recombineering. (C) Illustration of the 3^{rd} gain & loss selection system for identifying recombinant clones. Red asterisk (*) indicates the recombineering-positive clone. (D) Efficiency of the 2^{nd} recombineering after performing the 3^{rd} gain & loss selection system. Means \pm S.D., N = 3. (E) 2^{nd} recombineering scheme and position of colony PCR primers for recombination confirmation. (F) Picture of agarose gel electrophoresis showing colony PCR results. PCR product was only amplified in the recombineering-positive clone. Chromatogram results showing that the sequence of the amplified PCR product was conserved compared to the reference

sequence at the genome-CTC boundary.

Fig. 4. More strategies to increase recombination efficiency. (A) Picture of agarose gel electrophoresis showing the uncut BTV (7.6 kb; yellow rectangle), the linearized BTC (4.7 kb; red rectangle) and the vector backbone of BTV (2.9 kb; blue rectangle) after enzyme digestion of BTV with XhoI and XmaI. Efficiency of the 1st recombineering after performing the 1st gain & loss selection system. Means \pm S.D., N = 2. (B) Illustration of colonies in LB plate containing Amp after the 2nd BAC recombineering. After 48 h incubation at 32°C, colonies appeared. Large colonies (larger than 1 mm) were selected from one group and small colonies (smaller than 1 mm) from the other group. Efficiency of the 2nd recombineering after performing the 3rd gain & loss selection system in a larger or smaller colony-selected group. Means \pm S.D., N = 3.

Fig. 5. Summary of the experimental procedure and timing for each step.

Supplementary Fig. 1. Overview of the experiment procedure and estimated timing of each step.


Supplementary Fig. 2. Identification and procurement of the desired BAC.

Supplementary Fig. 3. Identification and procurement of the desired BAC.

Supplementary Fig. 4. Identification and procurement of the desired BAC.

Supplementary Fig. 5. Identification and procurement of the desired BAC.

Supplementary Fig. 6. Identification and procurement of the desired BAC.



Concentration	Diata	Colony Number				
of antibiotics	No	Experiment Group			DW	
	NU	#1	#2	#3	group	
Cam 12.5 µg/ml	1	1510	1672	1672		
	2	2455	1537	1457	0	
Kan 20 µg/ml	3	1403	1214	1591		
Cam 12.5 µg/ml	1	1915	1295	1618		
	2	1672	998	1187	0	
Kan 25 µg/ml	3	1430	1349	1457		
Cam 12.5 µg/ml	1	1726	2562	1861		
F3,	2	1672	1403	1295	0	
Kan 30 µg/ml	3	863	1295	998		

	Colony Number			
	Experiment Group			
	#1	#2	#3	
Number of inoculating c olony	48	48	48	
Number of positive colo ny	18	14	14	
Recombineering efficien cy (%)	37.50	29.17	29.17	
Means ± S.D of recomb ineering efficiency (%)	31.9	94 ± 3	.93	





Fig. 2


А




Concentration of a ntibiotics		Colony Number			
	Plate No	Expe	Experiment Group		
	NU -	#1	#2	#3	
Cam 12.5 µg/mL	1	970	749	1805	
	2	806	854	2150	
	3	595	1114	2035	

С


2nd gain & loss selection



Е




	Colony Numbe		
	Experiment Grou		
	#1	#2	#3
Number of inoculating c olony	48	48	48
Number of positive colo ny	48	48	48
Flip-out efficiency (%)	100	100	100
Means ± S.D of Flip-out efficiency (%)		100	




В

D




Concentration	Diata	Colony Number				
Concentration of antibiotics	Plate No	Expe	DW			
	INU	#1	#2	#3	group	
	1	324	432	243		
Amp 20 µg/ml	2	351	378	324	0	
	3	486	297	378		
	1	162	405	351		
Amp 30 µg/ml	2	162	108	189	0	
	3	324	135	378		
	1	243	81	189		
Amp 40 µg/ml	2	243	108	81	0	
	3	135	135	243		
		0	Colony	Numb	er	


	Colony Number			
	Experiment Group			
	#1	#2	#3	
Number of inoculating c olony	48	48	48	
Number of positive colo ny	37	36	36	
Recombineering efficien cy (%)	77.08	75.00	75.00	
Means ± S.D of recomb ineering efficiency (%)	75.6	69 ± 1.	20	



A	0.2 % agarose gel			
	and the second		Colony	Number
				ent Group
	10		#1	#2
	8 - 6 - Uncut BTV (7.6 kb)	Number of inoculating colo ny	48	48
	5 – Linearized BTC (4.7 kb) 4 – Vector backbone of BTV	Number of positive colony	31	26
	3 – (2.9 kb)	Recombineering efficiency (%)	64.58	54.17
	- The Control of Contr	Means ± S.D of recombine ering efficiency (%)	59.38	± 5.21
	larger than 1 mm	smaller than	1 mm	
	CTV AmpR ROSA26 BAC CamR	ROSA BA	426	₽3)
_	Colony Number	Colony (smaller than 1.	Colony	Number
	Colony (larger than 1 Experiment Group			ent Group
_	mm) <u>#1 #2 #3</u>	mm)		#2 #3
_	Number of inoculating c olony 16 16 16	Number of inoculating c olony	16	16 16
_	Number of positive colo ny 6 4 4	Number of positive colo ny	6	7 10
	Recombineering efficien cy (%) 37.50 25.00 25.00	Recombineering efficiency (%)	37.50 43	3.75 62.50
	<i>I</i> leans ± S.D of recomb ineering efficiency (%) 29.17 ± 5.89	Means ± S.D of recomb ineering efficiency (%)	47.92	±10.62



Supplementary Fig. 1



Supplementary Fig. 2


Ensembl blast/	BLAT VEP Tools BioMart Down	loads Help & Docs Blog	<i>C</i> Ensemb	A ^{65A} BLAST/BLAT VEP Te	ools BioMart Downloads Help & Docs Blog
ools BioMart Il tools Export cust Ensembl wi		nomes for your DNA Analyse your own variants and	Tools All tools	BioMart > Export custom datasets from Ensembl with this data-mining tool	BLAST/BLAT > Search our genomes for your DNA or protein sequence Analyse your own variant and predict the function consequences of know unknown variants
	Search All species v for All species Help and Documentation Favourite species Human	Go rs699 or coronary heart disease		Search Mouse ROSA26 e.g. BRCA2 or rat 5:627	• for Go 97383-63627669 or rs699 or coronary heart disease
enomes alect a species Aew full list of all Ensembl spe dit your favourites	Zebratish 	te genomes Human GRCh38.p12 GRCh372 Mouse GRCm38.p6 Zebrafish	All genomes Select a specie • <u>Miew full list of</u> • <u>Edit your favos</u>	all Ensembl species	Favourite genomes Fuman GRCh38.p12 Sit using GRCh372 Mouse GRCm38.p6
			D		
	/BLAT VEP Tools BioMart Dow	nloads Help & Docs Blog	D C Ensemb New Search	D 1 BLAST/BLAT VEP Tools T	BioMart Downloads Help & Docs Blog
Ensembl BLAST arch category to: 45 pt 67	//BLAT VEP Tools BioMart Dow ROSA26 112 results match ROSA26	nloads Help & Docs Blog Q		Only searching Mouse	
rch category to: 45 ot 67 species to: 107	RCSA26 112 results match ROSA26 Did you mean ¥ GIROSAX2550r (Mouse Gene Strat ENSAUS GROOM8429 e 113067425-11	In: reference (CL57BL6)) 907733-1	New Search Current selection: < al Species Only searching Mouse < al Categories Only searching Gene	Only searching Mouse 44 results match ROS/ <u>Did you mean</u> GHROSA/2650r/Mou ENSM05000006242	a Gene v ROSA25
category to: 45 ot 67 species to:	ROSA26 112 results match ROSA26 Did you mean v GNCOSA2550r (Mouse Gene. Strat Exististi Soforola 4: 1100r42.11 Gene trap ROSA 26; Philippe Solario GNCOSA2560r-201 (MGI transcript na an external reference matched to Trans Vanat trate + Phendype - Lozato + E GNROSA2560r-201 (MGI transcript	In: reference (CL578L5)) 397733-1 Source K01 Symbol.Acc K01104735] me record, description: gene tarp ROS4 26, Philippe Soriano, Is orget EVSMUST0000124246 semail Tark - Regulator + Orndosgue > Gene the ring: Strain: reference (CL578L5)	New Search Current selection: < all Species Only searching Mouse < all Categories	Only searching Mouse 44 results match ROS/ Did your mean CHICGSA/CSSCHUCE EXMIUS/COMPOSITION Gent tap ROSA/CSS- Gent tap ROSA/CSS- Gent tabe Panetgene an external reference in Submit date + Panetgene	ROSA26 RosA26 Category Gere X Species: Mouse X
rch 45 d 67 species to: 107 mouse 5	ROSA26 112 results match ROSA26 Did you mean v GIRCOSA255cr (Moyae Gene. Strat ENSMUS GOOMORE29 e 1105426-11 Gene trap ROSA 26, Philippe Solano J CarROSA23652-201 (MGI transcript na an external reference matched to Trans Vanita table - Phenotypes - Lozation - E GRICOSA265C7-201 (MGI transcript na GRICOSA265C7-201 MGI transcript na GRICOSA25C76-202 MGI transcript na GRICOSA25C767-202 MGI transcript na GRICOSA25C7767-202 MGI transcript na GRICOSA25C7	In: reference (CL578L5)) 307733-1 Source MGI Symbol.Acc: MGI:104735] me record: description: gene trap ROS64 26. Philippe Soriano, is cript ENSMUST00000124246 detaulate . Regulation + 2 orthologues + 0 cene tree refugl: Strain: reference (CL578L6)) 3077191-1 Source MGI Symbol.Acc: MGI:104735]. Source MGI Symbol.Acc: MGI:104735]. Soure & Strain: reference (CL578L6))	New Search Current selection: < all Species Only searching Mouse < all Categories Only searching Gene Restrict strains to: Mouse reference (CLS70L6 Mouse reference (CLS70L6	Only searching Mouse 44 results match ROS/ Did you mean	ROSA26 ROSA26 ROSA26 Control of Category Gere X Species: Mouse X Spe
rch 45 at 67 species to: 107 mouse 5 s: 50 100	ROSA26 112 results match ROSA26 Did you mean ¥ GIROSA/2550r (Mouse Gene. Strat ENSBUS GOODBA20 & 113067426-11 Gene turp ROSA 26, Philospe Safaaro GRROSA/2550r-204 (Moltarancight na an external reference matched to Trans Vanat tuide + Rondpase + Losato + E GIROSA/2550r-204 (Mouse Trans) ENSBUS TOODF6416 & 133067426-11 Gene turp ROSA 26, Philospe Safaaro Losation + Edman Reft + COLA seq + 1	In reference (CL57EL5)) Source MGI Symbol Acc MGI 104735] me record, description, grant trap ROSA 26, Philippe Soriano, is orget ENSMISTOROUT22476 strant Refs. + Regulation 701718-1 907178-1 90718-1 90718-1 90718-1 90718-1 90718-1 9071	New Search Current selection: < all Species Only searching Mouse < all Categories Only searching Gene Restlict strains to: Mouse Identics Strains Mouse ARRUJ Mouse ARRUJ Mouse ARRUJ	Only searching Mouse 44 results match ROS/ 44 results match ROS/ Did you mean	ROSA26 ROSA26 ROSA26 Control of Category Gere X Species: Mouse X See Gene. Strain - reference. (CLS7BL6.) (CLS7

Supplementary Fig. 3

Ensembl 🔤	STABLAT VEP Tools BloM	nt Downloads Help & Docs Blog 🔂 • Search all species		BLASTIBLAT VEP Tools BioMart Down	ioads Help & Docs Blog	Login¥ @ • Search all spacies
Mouse (GRCm38.p6) 🔻			Mouse (GRCm38;	p6) v		
6.113,067,428-113,077,333	Gene: Gt(ROSA)26Sor		Location: 6:113,067,230-113,07	77,531 Gene. GI(ROSA)26Sur		
sed displays nary ice variants	Gene: Gt(ROSA)265	OF EN SMUSG0000086429	Location-based displays - Whole genome	Chromosome 6: 113,067,23	0-113,077,531	
nscript comparison ne alleles	Description	gene trap ROSA 26, Philippe Scriano [Source MGI Symbol Acc MGI 104735 4]	- Chromosome summary - Region overview - Region in detail	\$<2%		
ance xondary Structure arativa Genomics	Gene Synonyms Location	Glopeo26, Girosa26, R26, ROISA26, Thumpd3as1, beta gee Chromosume 6: 113 (67:428-113) (77:333 revense strand.	E: Comparative Genomics	Assemblir exceptions chromosome 6	A2 834 AA4 8. 1989 83 64 (2)	
ornic alignments e tree	About this gene	GRCm38 CM010999.2 This gene has 4 transcripts (<u>splice variants). 3 orthologues</u> and is associated with <u>117 ortenotypes</u> .	- Alignments (mage) - Alignments (text) - Region Comparison	Assembly exceptions		
gain/loss tree logues oques	Transcripts	Show transcript table	E: Genetic Variation	Region in detail @		
mbl protein families ns	Summary Ø		- Resequencing - Strain table - Linkage Data	\$≺⊡⊒% উ⊄	100 M	Scroll:
es iological process	Name	GIROSA/2050rd* (MGI Symbol)	- Markers E: Other genome browsers	12.60 Mb	1/2 80 MB 1/8 00 MB	113.20 Mb 113.40 Mb
ellular component clecular function	Ensembl version	ENSMUSG000006429.9	- UCSC# NCBHP	Configs AC1570959 Genes	< AC153591.4 AC1586587 > AC155722.9 >	< AC153582.3 AC155287.6 > AC153910.6 >
pes Variation It table	Gene type Annotation method	LncRNA Manual annotation (determined on a case-by-case basis) from the <u>Havana</u> @project.	Configure this page	(Comprehensive set from GENCODE M22) **********************************	Gm44081 > 54	8.5 < LHgM Cpring > < Camict < RpussB (1710 > (ROSALDEDat Htmr14 > Engl1 > < Gm03589 Gm4200 > et5 > < Gm43955 < Table Gm04387 > Cwich :
t image ural variants pression	Go to Region in	Detail for more tracks and navigation options (e.g. zooming)	A Custom tracks	< Rad 18	< 0m1314 < 0m1365 0m13 < 0m136 0m13	991 > < Gm16161 TdB > Japn1 >
on			t) Export data DragSelect ↔ 11	Regulatory Build		
references ng evidence v	¢11 < ⊕ ⊒ % 5	-23.11 L	Event street	12.61 1/6	12.80 Mb 118.02 Me	112.20 M6 112.40 Mb
ristory	Genes (Comprehensive set Thum	113/09/6 111/09/6 111/09/6 111/09/6 111/09/6 111/09/6		Gene Legend marged Ensemblit	Reara	protested transpigt
gure this page	- prote	e coding protein coding	· · · · · · · · · · · · · · · · · · ·	Regulation Legend		RNA gara

Ensemble BLAST	BLAT VEP Confirme Descri	Tools BioMart Downloads Help & Do ew Image Configure Chromosome Image	rs Bloc Personal Data	_	🕅 • Search all stecies	0
M Find a track Active tracks	congue o terr	Select from available configurations:	Current unsaved	Save current confouration		
Favourite tracks In the Track order		Active tracks				. I
Search results		Sequence and assembly				
ion 🗄 Sequence and assembly	(25/63)	Contigs				+ 0
on - Sequence par - Markers	(2/4) (0/1)	Sequence				÷ě
nte - GRC alignments	(1/11)	Primary assembly mapping				÷õ -
91 - Simple features 01 - Clones & misc regions	(0.25)	B6Ng01 mouse dones				* 0
contras di situe. Tegente	(22/22)	C3H mouse clones				* 0
E Genes and transcripts	(2)66) (2)6)	CH25 mouse clones				* 0
- Genes - Longreads	(0/14)	CH26 mouse clones				* 0
Prediction transcripts	(0/1)	CH28 mouse clones				*0
RNASeq models	(0/45)	CH29 mouse clones				*0
B mRNA and protein alignments		CH33 mouse clones				*0
r g – mRNA alignments CSI – EST alignments	(1/3) (0/1)	CH34 mouse clones				* 0
CBI - Protein alignments	(1/4)	CH36 mouse clones				* 0
E Variation	(2/10)	CT7 mouse clones				* 0
 Sequence variants 	(1/3)	DN mouse clones				* 0
- Failed variants - Phenotype annotations	(0/1) (0/2)	MHPN mouse clones				* 0
Clearly and understa	(1/4)	MHPP mouse clones				* 0
Regulation	(1/248)	MM_DBa mouse clones				* 0
- Regulatory Build	(1/1)	MSMg01 mouse clones				÷ě
Heatures by CelVlissue	(0/241)	RP21 mouse clones				÷ŏ
- DNA methylation	(0/2)	PP22 mouse clones	112 80 MB	Constant of Landson of Lands	118.30 Mb	1000
	Gene Legend		12.80 Mb			140 Mb
		merged Ensembl(Havana posudogene		processed transcript RNA gene		

D		
CEnsembleus	TRLAT VEP Tools BioMart Downlow's Help & Docs Blog	Login Register 21 • Search af Svenies 🖉 🔍
Configure Region Image	Configure Overview Image Configure Chromosome Image Personal Data	
M 🔊	MM_DBa mouse clone ends	* 0 *
	MSMg01 mouse clone ends	* 0
Location:	RP21 mouse clone ends	* 0
Location-L	RP22 mouse clone ends	* 0
- Whole c	RP23 mouse clone ends	* 0
- Region	RP24 mouse clone ends	÷o
- Region	TSS (Eponine)	÷o
B Company	W1 mouse clone ands	* 0
- Synte	bMC mouse done ends	
– Align – Align	IRNAs	* 0
- Repk	B-90-45	* 0
E Genetic	Enable/disable all Clones & misc. regions	
- Variar	Change track style	
- Rese	Off	
- Stair		
- Markers		* 0 1011
E Other o	CH25 mouse dones	* 0
- UCSI	CH28 mouse clones	* 0 💻
- NCBI	CH29 mouse clones	* 0 < 0123
🗱 Carl	CH33 mouse dones	t 0
	CH34 mouse dones	* 0 *
👔 Cust	CH36 mause danes	÷Ö
	CT7 mouse dones	
ဖြစ်ခု	DN mouse climas	
Shar	M-IPN mouse clones	
		* 0
🖗 Book	MHPP mouse dates	* 0 *
	Gene Legend merged Ersembli Havana	processed transcript
	sseudogene	Rit4 pere
	Regulation Legend CTCF	Erhancer



Supplementary Fig. 5



WHEN SEARCHING FOR AVAILABILITY OF [BAC] CLONES, PLEASE USE THE Clone Information Search link

RPCI-24: Mouse (C57BL/6J Male) (*Mus* musculus) BAC Library

Background information



 Θ



Research

BAC Library Construction ALS Publications

The RPCI-24 BAC library has been constructed in our laboratory from tissues derived from The RPCT-24 BAC library has been constructed in our laboratory from tissues derived from single male CS2RL63 mouse (obtained from the Jackson Laboratory). Spleen and brain genomic DNA samples were isolated and partially digested with MboI. Size-selected MboI fragments were doned into the pTARBAC1 vector between the BamHI sites. The ligation products were transformed into DH10B electrocompetent cells (BRL Life Technologies). The library has been arrayed into 384-well microtiter dishes and also gridded onto 22x22cm yrdon <u>high-density filters</u> for screening by probe hybridization. Each hybridization membrane represents over 18,000 distinct mouse BAC clones, stamped in duplicate. The RPCI-24 Male (C57BL/6J) Mouse BAC Library

Segments	<u>Cloning</u> <u>Vector</u>	DNA	Restriction enzyme		Total Plates	Empty Wells	Empty Wells (%)	
1	pTARBAC1	Spleen	MboI	1-161, 168-177	288	3464	3.1	
		Brain	MboI	162-167, 178-288				
_		Brain	MboI	289-313				
2	pTARBAC1	Spleen	MboI	314-576	288	3951	3.6	
Total Library					576	7415	3.35	

I. 71

 $C \cdot H \cdot O \cdot R \cdot I$

Children's Hospital Oakland Research Institute

Vectors used in our libraries can be obtained upon request. The 'Resources and Research' section of our website provides <u>detailed map and sequence information</u>

Ordering & Pricing All vectors are available as Bacterial Stabs (DH10B) at the cost of \$100 plus an additional \$35 set-up fee. For shipping and general ordering details, please view the ordering & pricing information page.

For questions related to the site, please contact webmaster

Products

Home > Products > Vectors

Vectors information

about our vectors.

Ordering & Pricing

Home

Resources Online Ordering About Us

 \odot

Supplementary Fig. 6



WHEN SEARCHING FOR AVAILABILITY OF [BAC] CLONES, PLEASE USE THE Clone Information Search link

С 32k" BAC Re-Array Collection cedures line Mapping Resources wnload Page estions and Answers Research BAC Library Construction ALS Publications

News

You can find in the following a list of the different vectors we use in our libraries, click on the links in the table to obtain a map or the sequence of these vectors

Graphics	Genbank Files	Expandable graphics	Comments
attB-P[acman]-CmR- BW	g <u>enbank file</u>		
pBAC-lac	g <u>enbank file</u>		Not Available (BACPAC)
pBACe3.6	genbank file		
pBACGK1.1	g <u>enbank file</u>		
DBACGMR	genbank file		
pBAC-red	genbank file		
pCYPAC2	genbank file	wmf picture	
pEpiFOS5	genbank file		Order from Epicentre
pCC1FOS	genbank file		
pCC1FOS-CHA	genbank file		
pPAC4	genbank file	wmf picture	
pTARBAC1	genbank file	wmf picture	
pTARBAC1.3	g <u>enbank file</u>	wmf picture	
pTARBAC2	genbank file	wmf picture	
pTARBAC2.1	g <u>enbank file</u>	wmf picture	
pTARBAC3	genbank file	wmf picture	
pTARBAC4	g <u>enbank file</u>	wmf picture	
pTARBAC6	genbank file	wmf picture	

The Genbank sequence files of the cloning vectors can be downloaded and read with standard text editors. The files contain all sequence information plus a standard feature table. The .vmf picture format allows you to view and expand the vector image as you wish, in order to have the greatest amount of detail. After being downloaded, the clipart can be opened and printed using Microsoft Word. Informax offers a Freeware program for visualizing the molecular data of these vectors. <u>Vector NTL Viewer</u> is available for ev/ma/X/VP and Marintech (Sustem 7.1.2 or Jatar) nlaforms and enables the viewing